Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Department of Gastroenterology, Pisa University Hospital, Pisa, Italy.
Rodolfo
R
Sacco
Section of Radiology - Di.Bi.Me.F., University of Palermo, Palermo, Italy.
Michela
M
Antonucci
Department of Radiology, Pisa University Hospital, Pisa, Italy.
Irene
I
Bargellini
Department of Engineering, University of Trieste, Trieste, Italy.
Sara
S
Marceglia
Department of Gastroenterology, Pisa University Hospital, Pisa, Italy.
Valeria
V
Mismas
Section of Gastroenterology - Di.Bi.M.I.S., University of Palermo, Palermo, Italy.
Giuseppe
G
Cabibbo
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
HCC; TACE; combination therapy; intermediate stage; sorafenib